Learning objectives

After watching this webinar, participants will be aware of: 

• 2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias;
• limitations of Class III antiarrhythmic drugs;
• evidence-based pharmacotherapy for the acute management of electrical storm and recurrent episodes of ventricular arrhythmias.

Needs assessment and expected educational outcome

To update cardiologists on the role of intravenous, ultrashort-acting beta-blockers in the management of electrical storm and recurrent episodes of VA, as well as to provide the latest evidence about the role of intravenous, short-acting beta-blockers for acute treatment of atrial arrhythmias in critically ill patients.

Main topic

• Antiarrhythmic Drug Treatment - Arrhythmias, General

Related topics

• Treatment - Atrial Fibrillation (AF) - Acute Management
• Treatment - Supraventricular Tachycardia (Non-Atrial Fibrillation)
• Ventricular Arrhythmias and Sudden Cardiac Death (SCD) - Drug Treatment of Ventricular Arrhythmias

Session information

EHRA Core Cardiology webinars are designed to present fundamentals in arrhythmias and are addressed to general cardiologists and electrophysiologists in training (COT and also young EHRA members).

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

Looking for more essentials on the 2022 ESC Guidelines on ventricular arrhythmias? Watch the ESC 2022 Clinical Practice Guidelines Series on ventricular arrhythmias webinar on-demand here.

Technical settings

The webinar is available on PC and tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).